Jaclynne H. Nader
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jaclynne H. Nader has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Clement Ma
Harvard Medical School Boston Massachusetts
1 shared publication- David S. Shulman
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA
1 shared publication Dylan V. Neel
Harvard Medical School Boston Massachusetts
1 shared publicationFlorence Bourgeois
Harvard Medical School Boston Massachusetts
1 shared publication- Steven G. DuBois
Department of Pediatrics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA
1 shared publication
Latest Publications
- 4 September 2020
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (11) , e28694
Landscape of phase 1 clinical trials for minors with cancer in the United States
Objectives: Understanding trends in characteristics of early phase trials that allow minors with cancer to participate may inform additional efforts to improve cancer drug development for young people.Methods: We accessed data for oncology phase 1 or phase 1/2 trials in the United States from ClinicalTrials.gov with lower age bound for eligibility P ≤ .02). No other temporal trends were seen. The median times from first‐in‐adult to first‐in‐pediatric for monotherapy and combination trials were 5.7 and 3.3 years, respectively.Conclusion: The paucity of clear temporal trends highlights the need for innovation in early drug development for young people. Our analysis serves as a benchmark against which to evaluate initiatives to improve pediatric cancer drug development.
- 4 September 2020
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (11) , e28694
Landscape of phase 1 clinical trials for minors with cancer in the United States
Objectives: Understanding trends in characteristics of early phase trials that allow minors with cancer to participate may inform additional efforts to improve cancer drug development for young people.Methods: We accessed data for oncology phase 1 or phase 1/2 trials in the United States from ClinicalTrials.gov with lower age bound for eligibility P ≤ .02). No other temporal trends were seen. The median times from first‐in‐adult to first‐in‐pediatric for monotherapy and combination trials were 5.7 and 3.3 years, respectively.Conclusion: The paucity of clear temporal trends highlights the need for innovation in early drug development for young people. Our analysis serves as a benchmark against which to evaluate initiatives to improve pediatric cancer drug development.